Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1109-1119

  Gonzalez Angulo, Ana M ^a   Iwamoto, Takayuki ^a   Liu, Shuying ^a   Chen, Huiqin ^a   Do, Kim Anh ^a   Hortobagyi, Gabriel N ^a   Mills, Gordon B ^a   Meric Bernstam, Funda ^a   Symmans, W Fraser ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SONIC HEDGEHOG PROTEIN;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CD44 GENE; CDH1 GENE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MASTECTOMY; NUCLEOTIDE SEQUENCE; ONCOGENE; PARTIAL MASTECTOMY; PCNA GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SLUG GENE; SNAIL GENE; SOX9 GENE; TGFBETA GENE; TWIST GENE;

BREAST NEOPLASMS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84863134360     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2762     Document Type: Article

References (26)

1. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, et al. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008;26:806-13. (Pubitemid 351264394)
2. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9. (Pubitemid 29075229)
3. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
4. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44. (Pubitemid 46638799)
5. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22. (Pubitemid 350013847)
6. O'Regan RM, Von Roenn JH, Carlson RW, Malik U, Sparano JA, Staradub V, et al. Final results of a phase II trial of preoperative TAC (Docetaxel/ doxorubicin/cyclophosphamide) in stage III breast cancer. Clin Breast Cancer 2005;6:163-8. (Pubitemid 40975613)
7. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003;9:124-33. (Pubitemid 36109724)
8. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2009;108:183-90. (Pubitemid 351311360)
9. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
10. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010;28:4316-23.
11. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, et al. Total RNA yield and microarray gene expression profiles from fine needle aspiration and core needle biopsy samples of breast cancer. Cancer 2003;97:2960-71. (Pubitemid 36676249)
12. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Different molecular subtypes of breast cancer respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85. (Pubitemid 41170290)
13. Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, et al. Comparison of the predictive accuracy of DNA array based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 2005;7:357-67. (Pubitemid 41149651)
14. Johnson WE, Rabinovic A, Li C. Adjusting batch effects in microarray expression data using Empirical Bayes methods. Biostatistics 2007;8:118-27. (Pubitemid 44906106)
15. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007;8:203-11.
16. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2010;27:1160-7.
17. Efron B, Tishirani R. On testing the significance of sets of genes. Ann Appl Stat 2007;1:107-29.
18. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
19. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer 2012;130:808-16.
20. Jiang Z, Gentleman R. Extensions to gene set enrichment. Bioinformatics 2007;23:306-13. (Pubitemid 46323152)
21. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, et al. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res 2006;12:1721-7.
22. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003;97:2960-71. (Pubitemid 36676249)
23. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-13.
24. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor negative and HER2 positive breast cancers. Breast Cancer Res 2009;11:R15.
25. Karn T, Pusztai L, Ruckhaeberle E, Liedtke C, Muller V, Schmidt M, et al. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 2012;48:12-23.
26. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.